...
首页> 外文期刊>Acute cardiac care >Prevention of contrast-induced nephropathy with haemofiltration in high-risk patients after percutaneous coronary intervention.
【24h】

Prevention of contrast-induced nephropathy with haemofiltration in high-risk patients after percutaneous coronary intervention.

机译:经皮冠状动脉介入治疗后高危患者的血液滤过预防对比剂诱发的肾病。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The incidence of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) is increasing. The aim of the study is to assess the benefits of prophylactic haemofiltration (PHF) in patients with high risk of developing CIN after PCI. METHODS: 20 patients who underwent PHF after PCI in the context of acute coronary syndrome were selected retrospectively and compared with 20 matched controls with similar risk characteristics. The main variable analysed was the appearance of CIN and the secondary variables were the development of acute clinical kidney failure, heart failure, therapeutic HF and mortality. RESULTS: The baseline characteristics were similar in both groups, with reference creatinine of 2.4 +/- 1.3 mg/dl, contrast used 392 +/- 213 cc and Mehran score of 21.9 +/- 5.2 in the PHF group, as opposed to values of 2.0 +/- 0.6 mg/dl, 368 +/- 126 cc and 20.2 +/- 6.9 respectively in controls. The incidence of CIN was of 6 patients (30%) in the PHF group and 13 patients (65%) in the control group (P=0.03). There were no significant differences in the rest of the variables studied. CONCLUSION: Haemofiltration after PCI may be an effective strategy for the prevention of CIN in patients at high risk of developing it.
机译:背景:经皮冠状动脉介入治疗(PCI)后,造影剂诱发的肾病(CIN)的发生率正在增加。该研究的目的是评估预防性血液滤过(PHF)对PCI后发生CIN的高风险患者的益处。方法:回顾性选择20例在急性冠脉综合征中接受PCI后接受PHF的患者,并与20名具有相似风险特征的对照进行比较。分析的主要变量是CIN的出现,次要变量是急性临床肾衰竭,心力衰竭,治疗性心衰和死亡率的发展。结果:两组患者的基线特征相似,参考肌酐为2.4 +/- 1.3 mg / dl,对比剂使用HF 392 +/- 213 cc,Mehran评分为21.9 +/- 5.2,与之相反在对照中分别为2.0 +/- 0.6mg / dl,368 +/- 126cc和20.2 +/- 6.9。 PHF组的CIN发生率为6例(30%),对照组的CIN发生率为13例(65%)(P = 0.03)。在其余的研究变量中没有显着差异。结论:PCI后的血液滤过可能是预防CIN的高发风险患者的有效策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号